PUBLISHER: DelveInsight | PRODUCT CODE: 1854954
PUBLISHER: DelveInsight | PRODUCT CODE: 1854954
DelveInsight's "Optic Neuritis - Epidemiology Forecast - 2034" report delivers an in-depth understanding of optic neuritis, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Study Period: 2020-2034
Disease Understanding
Optic Neuritis Overview
Optic neuritis is an inflammation of the optic nerve, which transmits visual signals from the eye to the brain. The condition often presents with sudden vision loss, pain on eye movement, and altered color perception. It can affect one or both eyes and is frequently linked to autoimmune or neurological disorders, particularly multiple sclerosis and neuromyelitis optica spectrum disorder (NMOSD).
The causes of optic neuritis are multifactorial. Autoimmune conditions, including multiple sclerosis, NMOSD, lupus, and sarcoidosis, are prominent contributors, with NMOSD cases often involving bilateral and more severe vision loss. Infections such as herpes zoster, Epstein-Barr virus (EBV), syphilis, and Lyme disease can trigger immune-mediated inflammation of the optic nerve. Additional risk factors include post-viral or post-vaccination immune responses, exposure to toxins like methanol or ethambutol, and genetic predispositions such as HLA-DRB1 and HLA-B27.
Clinically, optic neuritis typically manifests as acute, unilateral vision loss, although bilateral involvement can occur. Severity ranges from mild blurring to complete blindness. Eye pain, especially with movement, is common and often precedes visual changes. Patients may also experience reduced color vision (dyschromatopsia), decreased contrast sensitivity, and a Relative Afferent Pupillary Defect (RAPD) in unilateral or asymmetric cases. On fundoscopic examination, the optic disc may appear normal in retrobulbar neuritis or swollen (papillitis) when the anterior optic nerve is inflamed.
Optic Neuritis Diagnosis
Diagnosis of optic neuritis relies on a combination of clinical assessment and advanced imaging. Magnetic Resonance Imaging (MRI) of the brain and orbits with gadolinium contrast is the preferred modality, revealing optic nerve inflammation and potential demyelinating lesions suggestive of multiple sclerosis. Visual field testing evaluates the pattern of vision loss, while Optical Coherence Tomography (OCT) quantifies Retinal Nerve Fiber Layer (RNFL) thinning. In suspected infectious or autoimmune cases, further workup includes serologic tests, cerebrospinal fluid (CSF) analysis via lumbar puncture, and antibody screening, such as Aquaporin-4 (AQP4) for NMOSD.
Several conditions can mimic optic neuritis, making differential diagnosis essential. Anterior Ischemic Optic Neuropathy (AION) typically occurs in older adults with vascular risk factors and presents as painless vision loss; arteritis AION involves systemic symptoms like headache and jaw claudication. Leber's Hereditary Optic Neuropathy (LHON) causes bilateral, subacute vision loss in young men and is maternally inherited. Toxic and nutritional optic neuropathies arise from substances like methanol or vitamin B12 deficiency. Compressive optic neuropathies, from tumors or thyroid disease, are confirmed via MRI.
The optic neuritis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of optic neuritis, gender-specific incident cases of optic neuritis, severity-specific incident cases of optic neuritis, age-specific incident cases of optic neuritis and site-specific incident cases of optic neuritis in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
KOL Views
DelveInsight's analysts collaborated with over 50 key opinion leaders (KOLs), conducting in-depth interviews with more than 30 experts across the 7MM. To keep pace with evolving epidemiology trends, the team gathered first-hand insights from KOLs and subject matter experts (SMEs) through primary research, addressing data limitations and reinforcing findings from secondary research. These professionals offered valuable input on the optic neuritis landscape, highlighting patient behavior trends, and challenges in access to care. Contributors included experts from renowned institutions such as the Baylor College of Medicine and Methodist Hospital, US; University of Minnesota, US; University of Freiburg, Germany; Hospital St Louis, France; University of Siena, Italy; University of Valencia, Spain; University Forvie Site, UK; Jichi Medical University, Japan; and Chiba University, Japan; among others.
According to US KOLs, "There is a significant gap in optic neuritis care, as rising incidence is accompanied by persistent challenges in timely diagnosis due to overlapping symptoms with other neurological disorders, often leading to preventable vision loss and disease advancement."
According to European KOLs, "Optic neuritis presents acute severity with sudden, painful vision loss, while chronic cases carry the risk of ongoing visual impairment and recurrence, potentially causing irreversible damage-emphasizing its serious clinical nature and lasting impact on patients' quality of life."
According to Japanese KOLs, "The increasing burden of optic neuritis, especially in aging populations, noting that the condition's heterogeneity creates substantial obstacles for prompt diagnosis and consistent disease monitoring."
Epidemiology Insights
Optic Neuritis to Buy
The optic neuritis epidemiology report for the 7MM covers the forecast period from 2025 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.
The highest cases of optic neuritis were found in Germany among EU4 and the UK in 2024.
Epidemiological data is collected through surveys, health records, and other sources. It is then analyzed to calculate incidence rates, identify trends, and project future disease burdens using mathematical models.
The highest cases of optic neuritis were found in the US among the 7MM in 2024.